(Reuters) – AstraZeneca Plc <AZN.L> said on Monday U.S. regulators approved its diabetes drug Farxiga to be used as a treatment to reduce the chances of hospitalisation for heart failure in adults with type-2 diabetes and other cardiovascular risks.
The approval by the U.S. Food and Drug Administration is based on results from the DECLARE-TIMI 58 clinical trial, the British drugmaker said and follows a similar approval https://www.astrazeneca.com/media-centre/press-releases/2019/forxiga-label-updated-in-the-eu-in-type-2-diabetes.html by the European authorities in August.
Diabetes is associated with a high risk of heart failure.
(Reporting by Pushkala Aripaka in Bengaluru; Editing by Arun Koyyur)